anurajms/meta_analysis huggingface dataset:
MESH terms:
Impact of Haemophilus influenzae type B (Hib) and viral influenza vaccinations in pregnancy for improving maternal, neonatal and infant health outcomes
1. *Vaccination; 2. Haemophilus influenzae type b [*immunology]; 3. Influenza Vaccines [*administration & dosage, immunology]; 4. Influenza, Human [immunology, *prevention & control]; 5. Pregnancy Complications, Infectious [immunology, *prevention & control]; 6. Pregnancy Outcome; 7. Randomized Controlled Trials as Topic; 8. Vaccines, Inactivated [administration & dosage, immunology];
MESH terms:
Antibiotic lock for the prevention of catheter‐related infection in neonates
1. Amoxicillin [therapeutic use]; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Catheter‐Related Infections [*prevention & control]; 4. Catheterization, Central Venous [*methods]; 5. Central Venous Catheters [*adverse effects]; 6. Confidence Intervals; 7. Fluconazole [therapeutic use]; 8. Gentamicins [therapeutic use]; 9. Intensive Care Units, Neonatal; 10. Randomized Controlled Trials as Topic; 11. Selection Bias; 12. Vancomycin [therapeutic use];
MESH terms:
Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures
1. *Antibiotic Prophylaxis; 2. Cerebrospinal Fluid Leak [complications]; 3. Cerebrospinal Fluid Rhinorrhea [complications]; 4. Meningitis, Bacterial [etiology, *prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Skull Fracture, Basilar [*complications];
MESH terms:
Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection
1. *Pneumocystis carinii; 2. AIDS‐Related Opportunistic Infections [*drug therapy]; 3. Adrenal Cortex Hormones [*therapeutic use]; 4. Chemotherapy, Adjuvant; 5. Hypoxia [etiology, therapy]; 6. Pneumonia, Pneumocystis [*drug therapy]; 7. Randomized Controlled Trials as Topic; 8. Respiration, Artificial;
MESH terms:
Leukotriene inhibitors for bronchiolitis in infants and young children
1. Acetates [adverse effects, *therapeutic use]; 2. Bronchiolitis [*drug therapy]; 3. Cyclopropanes; 4. Length of Stay; 5. Leukotriene Antagonists [adverse effects, *therapeutic use]; 6. Quinolines [adverse effects, *therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Sulfides;
MESH terms:
Azithromycin for acute lower respiratory tract infections
1. Acute Disease; 2. Amoxicillin [*therapeutic use]; 3. Amoxicillin‐Potassium Clavulanate Combination [*therapeutic use]; 4. Anti‐Bacterial Agents [*therapeutic use]; 5. Azithromycin [*therapeutic use]; 6. Bronchitis [*drug therapy]; 7. Drug Therapy, Combination; 8. Pneumonia [*drug therapy]; 9. Randomized Controlled Trials as Topic; 10. Respiratory Tract Infections [drug therapy]; 11. Treatment Failure;
MESH terms:
Chlorhexidine skin or cord care for prevention of mortality and infections in neonates
1. *Infant Mortality; 2. Anti‐Infective Agents, Local [*therapeutic use]; 3. Bacterial Infections [mortality, *prevention & control]; 4. Chlorhexidine [*therapeutic use]; 5. Inflammation [prevention & control]; 6. Randomized Controlled Trials as Topic; 7. Skin [*microbiology]; 8. Umbilical Cord [*microbiology]; 9. Umbilicus; 10. Vagina [microbiology];
MESH terms:
Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
1. Dehydration [etiology, *therapy]; 2. Disease Management; 3. Hemorrhagic Fever, Ebola [*complications]; 4. Hypodermoclysis; 5. Infusions, Intraosseous; 6. Infusions, Intravenous; 7. Infusions, Parenteral [*methods]; 8. Saphenous Vein;
MESH terms:
Corticosteroids for parasitic eosinophilic meningitis
1. Central Nervous System Parasitic Infections [*drug therapy]; 2. Eosinophilia [*drug therapy]; 3. Glucocorticoids [*therapeutic use]; 4. Meningitis [*drug therapy]; 5. Prednisolone [*therapeutic use]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Routine blood cultures in the management of pyelonephritis in pregnancy for improving outcomes
1. Microbiological Techniques; 2. Pregnancy Complications, Infectious [*blood, therapy]; 3. Pyelonephritis [*blood];
MESH terms:
Skin preparation with alcohol versus alcohol followed by any antiseptic for preventing bacteraemia or contamination of blood for transfusion
1. *Blood Donors; 2. Anti‐Infective Agents, Local [*administration & dosage]; 3. Bacteremia [*prevention & control]; 4. Blood Transfusion; 5. Disinfection [*methods]; 6. Ethanol [*administration & dosage]; 7. Skin [*microbiology];
MESH terms:
Low dose versus high dose stavudine for treating people with HIV infection
1. Anti‐HIV Agents [*administration & dosage, adverse effects]; 2. Developing Countries; 3. HIV Infections [*drug therapy, virology]; 4. HIV‐1; 5. Randomized Controlled Trials as Topic; 6. Stavudine [*administration & dosage, adverse effects]; 7. Viral Load [drug effects];
MESH terms:
Macrolides for diffuse panbronchiolitis
1. Anti‐Bacterial Agents [*therapeutic use]; 2. Bronchiolitis [diagnostic imaging, *drug therapy]; 3. Erythromycin [*therapeutic use]; 4. Haemophilus Infections [diagnostic imaging, *drug therapy]; 5. Macrolides [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Tomography, X‐Ray Computed;
MESH terms:
Pneumococcal vaccination during pregnancy for preventing infant infection
1. Gestational Age; 2. Pneumococcal Infections [immunology, *prevention & control]; 3. Pneumococcal Vaccines [*administration & dosage]; 4. Randomized Controlled Trials as Topic; 5. Vaccination [*methods];
MESH terms:
Adjunctive hyperbaric oxygen for necrotizing fasciitis
1. Fasciitis, Necrotizing [*therapy]; 2. Hyperbaric Oxygenation [*methods];
MESH terms:
Antibiotics for community‐acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children
1. *Mycoplasma pneumoniae; 2. Amoxicillin‐Potassium Clavulanate Combination [therapeutic use]; 3. Anti‐Bacterial Agents [*therapeutic use]; 4. Azithromycin [therapeutic use]; 5. Bronchitis [*drug therapy, microbiology]; 6. Community‐Acquired Infections [drug therapy, microbiology]; 7. Erythromycin [therapeutic use]; 8. Pneumonia, Mycoplasma [*drug therapy]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Antibiotic regimens for management of intra‐amniotic infection
1. *Amnion; 2. Ampicillin [therapeutic use]; 3. Anti‐Bacterial Agents [*therapeutic use]; 4. Cefotetan [therapeutic use]; 5. Chorioamnionitis [*drug therapy]; 6. Clindamycin [therapeutic use]; 7. Delivery, Obstetric; 8. Drug Administration Schedule; 9. Endometritis [etiology]; 10. Fetal Diseases [etiology]; 11. Gentamicins [therapeutic use]; 12. Postpartum Period; 13. Sepsis [etiology]; 14. Sulbactam [therapeutic use];
MESH terms:
Surfactant for meconium aspiration syndrome in term and late preterm infants
1. Extracorporeal Membrane Oxygenation [statistics & numerical data]; 2. Meconium Aspiration Syndrome [*drug therapy, mortality]; 3. Pulmonary Surfactants [*therapeutic use]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Vaginal chlorhexidine during labour to prevent early‐onset neonatal group B streptococcal infection
1. *Streptococcus agalactiae; 2. Administration, Intravaginal; 3. Anti‐Infective Agents, Local [*administration & dosage]; 4. Chlorhexidine [*administration & dosage]; 5. Labor, Obstetric; 6. Randomized Controlled Trials as Topic; 7. Streptococcal Infections [*prevention & control]; 8. Vaginal Creams, Foams, and Jellies [administration & dosage];
MESH terms:
Timing of intravenous prophylactic antibiotics for preventing postpartum infectious morbidity in women undergoing cesarean delivery
1. Anti‐Bacterial Agents [*administration & dosage]; 2. Antibiotic Prophylaxis [*standards]; 3. Cesarean Section [*adverse effects]; 4. Drug Administration Schedule; 5. Endometritis [prevention & control]; 6. Injections, Intravenous; 7. Randomized Controlled Trials as Topic; 8. Surgical Wound Infection [*prevention & control]; 9. Urinary Tract Infections [prevention & control];
MESH terms:
Amantadine and rimantadine for influenza A in children and the elderly
1. *Influenza A virus; 2. Amantadine [adverse effects, *therapeutic use]; 3. Antiviral Agents [adverse effects, *therapeutic use]; 4. Influenza A Virus, H1N1 Subtype; 5. Influenza, Human [*prevention & control]; 6. Randomized Controlled Trials as Topic; 7. Rimantadine [adverse effects, *therapeutic use]; 8. Sex Factors;
MESH terms:
Antibiotics for meconium‐stained amniotic fluid in labour for preventing maternal and neonatal infections
1. *Amniotic Fluid; 2. *Labor, Obstetric; 3. *Meconium; 4. Ampicillin [therapeutic use]; 5. Anti‐Bacterial Agents [*therapeutic use]; 6. Chorioamnionitis [*prevention & control]; 7. Endometritis [prevention & control]; 8. Intensive Care Units, Neonatal [statistics & numerical data]; 9. Randomized Controlled Trials as Topic; 10. Sepsis [prevention & control]; 11. Sulbactam [therapeutic use];
MESH terms:
Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator‐associated pneumonia
1. Bacteriological Techniques [*methods]; 2. Bronchoalveolar Lavage [methods, mortality]; 3. Bronchoscopy [methods, mortality]; 4. Immunocompetence; 5. Intensive Care Units [statistics & numerical data]; 6. Length of Stay; 7. Pneumonia, Ventilator‐Associated [*microbiology, mortality]; 8. Randomized Controlled Trials as Topic; 9. Respiratory System [*metabolism];
MESH terms:
Strategies of testing for syphilis during pregnancy
1. *Point‐of‐Care Systems; 2. Pregnancy Complications, Infectious [*diagnosis]; 3. Prenatal Diagnosis [*methods]; 4. Randomized Controlled Trials as Topic; 5. Syphilis [*diagnosis]; 6. Syphilis, Congenital [diagnosis];
MESH terms:
Antibiotics for community‐acquired pneumonia in adult outpatients
1. Anti‐Bacterial Agents [adverse effects, *therapeutic use]; 2. Community‐Acquired Infections [drug therapy]; 3. Outpatients; 4. Pneumonia [*drug therapy]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Antibiotics for bronchiolitis in children under two years of age
1. Ampicillin [therapeutic use]; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Azithromycin [therapeutic use]; 4. Bronchiolitis [*drug therapy, mortality]; 5. Clarithromycin [therapeutic use]; 6. Erythromycin [therapeutic use]; 7. Length of Stay; 8. Randomized Controlled Trials as Topic;
MESH terms:
Prophylaxis for Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients
1. *Immunocompromised Host; 2. Anti‐Infective Agents [adverse effects, *therapeutic use]; 3. HIV Seronegativity; 4. Pneumonia, Pneumocystis [*prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Trimethoprim, Sulfamethoxazole Drug Combination [adverse effects, *therapeutic use];
MESH terms:
Acellular vaccines for preventing whooping cough in children
1. Age Factors; 2. Diphtheria‐Tetanus‐Pertussis Vaccine [adverse effects, *therapeutic use]; 3. Diphtheria‐Tetanus‐acellular Pertussis Vaccines [adverse effects, therapeutic use]; 4. Pertussis Vaccine [therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Whooping Cough [*prevention & control];
MESH terms:
Topical antifungal treatments for tinea cruris and tinea corporis
1. Administration, Cutaneous; 2. Adrenal Cortex Hormones [therapeutic use]; 3. Allylamine [analogs & derivatives, therapeutic use]; 4. Antifungal Agents [administration & dosage, *therapeutic use]; 5. Azoles [therapeutic use]; 6. Benzoates [therapeutic use]; 7. Drug Combinations; 8. Naphthalenes [therapeutic use]; 9. Pruritus [*drug therapy]; 10. Randomized Controlled Trials as Topic; 11. Salicylates [therapeutic use]; 12. Terbinafine; 13. Tinea [*drug therapy];
MESH terms:
Structural and community‐level interventions for increasing condom use to prevent the transmission of HIV and other sexually transmitted infections
1. Chlamydia Infections [epidemiology, prevention & control]; 2. Condoms [*statistics & numerical data]; 3. Gonorrhea [epidemiology, prevention & control]; 4. HIV Infections [epidemiology, prevention & control]; 5. Health Promotion [*organization & administration]; 6. Herpes Genitalis [epidemiology, prevention & control]; 7. Herpesvirus 2, Human; 8. Incidence; 9. Prevalence; 10. Randomized Controlled Trials as Topic; 11. Sexually Transmitted Diseases [epidemiology, *prevention & control]; 12. Syphilis [epidemiology, prevention & control]; 13. Trichomonas Infections [epidemiology, prevention & control];
MESH terms:
Antibiotics for acute pyelonephritis in children
1. Acute Disease; 2. Administration, Oral; 3. Anti‐Bacterial Agents [administration & dosage, *therapeutic use]; 4. Drug Therapy, Combination; 5. Injections, Intravenous; 6. Pyelonephritis [*drug therapy]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection
1. *CCR5 Receptor Antagonists; 2. Anti‐HIV Agents [*therapeutic use]; 3. Antibodies, Monoclonal [*therapeutic use]; 4. Antibodies, Monoclonal, Humanized [*therapeutic use]; 5. Drug Administration Schedule; 6. HIV Antibodies [*therapeutic use]; 7. HIV Infections [*drug therapy]; 8. HIV‐1 [*genetics]; 9. RNA, Viral [blood]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Corticosteroids for dengue infection
1. Adrenal Cortex Hormones [*therapeutic use]; 2. Blood Transfusion [statistics & numerical data]; 3. Randomized Controlled Trials as Topic; 4. Severe Dengue [*drug therapy, mortality]; 5. Shock, Hemorrhagic [*drug therapy, mortality];
MESH terms:
Vaccines for post‐exposure prophylaxis against varicella (chickenpox) in children and adults
1. *Herpesvirus 3, Human; 2. Chickenpox [*prevention & control, transmission]; 3. Chickenpox Vaccine [*administration & dosage]; 4. Post‐Exposure Prophylaxis [*methods]; 5. Randomized Controlled Trials as Topic; 6. Vaccines, Attenuated [administration & dosage];
MESH terms:
Bronchodilators for bronchiolitis
1. Acute Disease; 2. Albuterol [therapeutic use]; 3. Ambulatory Care [statistics & numerical data]; 4. Bronchiolitis [blood, *drug therapy]; 5. Bronchodilator Agents [*therapeutic use]; 6. Hospitalization [statistics & numerical data]; 7. Oxygen [blood]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Intrapartum antibiotics for known maternal Group B streptococcal colonization
1. *Labor, Obstetric; 2. *Streptococcus agalactiae; 3. Ampicillin [therapeutic use]; 4. Anti‐Bacterial Agents [*therapeutic use]; 5. Antibiotic Prophylaxis [*methods]; 6. Carrier State [*drug therapy]; 7. Infectious Disease Transmission, Vertical [*prevention & control]; 8. Penicillin G [therapeutic use]; 9. Penicillins [therapeutic use]; 10. Streptococcal Infections [prevention & control, *transmission];
MESH terms:
Hormonal contraception for women exposed to HIV infection
1. Contraception [*adverse effects, methods]; 2. Contraceptives, Oral, Hormonal [administration & dosage, *adverse effects]; 3. Estrogens [administration & dosage, adverse effects]; 4. HIV Infections [*transmission]; 5. Progestins [administration & dosage, adverse effects];
MESH terms:
Post‐exposure passive immunisation for preventing measles
1. Cohort Studies; 2. Immunization, Passive [*methods]; 3. Measles [*prevention & control]; 4. Post‐Exposure Prophylaxis [*methods]; 5. Randomized Controlled Trials as Topic; 6. gamma‐Globulins [administration & dosage];
MESH terms:
Systemic corticosteroids for acute sinusitis
1. Acute Disease; 2. Administration, Oral; 3. Adrenal Cortex Hormones [*therapeutic use]; 4. Anti‐Bacterial Agents [*therapeutic use]; 5. Anti‐Inflammatory Agents, Non‐Steroidal [therapeutic use]; 6. Betamethasone [therapeutic use]; 7. Prednisone [therapeutic use]; 8. Randomized Controlled Trials as Topic; 9. Sinusitis [*drug therapy];
MESH terms:
Over‐the‐counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults
1. Acute Disease; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Antitussive Agents [*therapeutic use]; 4. Chemotherapy, Adjuvant [methods]; 5. Cough [*drug therapy, etiology]; 6. Drug Therapy, Combination [methods]; 7. Expectorants [therapeutic use]; 8. Nonprescription Drugs [*therapeutic use]; 9. Pneumonia [complications, *drug therapy]; 10. Randomized Controlled Trials as Topic; 11. Treatment Outcome;
MESH terms:
Intermittent versus daily therapy for treating tuberculosis in children
1. Antitubercular Agents [*therapeutic use]; 2. Drug Administration Schedule; 3. Randomized Controlled Trials as Topic; 4. Tuberculosis, Pulmonary [*drug therapy];
MESH terms:
Beta lactam antibiotic monotherapy versus beta lactam‐aminoglycoside antibiotic combination therapy for sepsis
1. Aminoglycosides [adverse effects, *therapeutic use]; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Bacterial Infections [*drug therapy]; 4. Cause of Death; 5. Drug Therapy, Combination [methods]; 6. Gram‐Negative Bacterial Infections [drug therapy]; 7. Gram‐Positive Bacterial Infections [drug therapy]; 8. Randomized Controlled Trials as Topic; 9. beta‐Lactams [*therapeutic use];
MESH terms:
Intranasal steroids for acute sinusitis
1. Acute Disease; 2. Administration, Intranasal; 3. Adrenal Cortex Hormones [*administration & dosage]; 4. Randomized Controlled Trials as Topic; 5. Sinusitis [*drug therapy];
MESH terms:
Infection control strategies for preventing the transmission of meticillin‐resistant Staphylococcus aureus (MRSA) in nursing homes for older people
1. *Homes for the Aged; 2. *Nursing Homes; 3. Cross Infection [*prevention & control, transmission]; 4. Infection Control [*methods]; 5. Methicillin‐Resistant Staphylococcus aureus [*drug effects]; 6. Staphylococcal Infections [*prevention & control, transmission];
MESH terms:
Antibiotic therapy for the treatment of methicillin‐resistant Staphylococcus aureus (MRSA) in non surgical wounds
1. *Methicillin‐Resistant Staphylococcus aureus; 2. Amoxicillin‐Potassium Clavulanate Combination [therapeutic use]; 3. Anti‐Bacterial Agents [*therapeutic use]; 4. Diabetic Foot [*complications]; 5. Randomized Controlled Trials as Topic; 6. Staphylococcal Infections [*drug therapy];
MESH terms:
Continuous negative extrathoracic pressure or continuous positive airway pressure compared to conventional ventilation for acute hypoxaemic respiratory failure in children
1. Bronchiolitis [therapy]; 2. Continuous Positive Airway Pressure [methods]; 3. Dengue [complications]; 4. Hypoxia [*therapy]; 5. Respiration, Artificial [*methods]; 6. Respiratory Insufficiency [*therapy]; 7. Ventilators, Negative-Pressure;
MESH terms:
Combined and alternating paracetamol and ibuprofen therapy for febrile children
1. Acetaminophen [*administration & dosage]; 2. Antipyretics [*administration & dosage]; 3. Body Temperature [drug effects]; 4. Combined Modality Therapy [adverse effects, methods]; 5. Fever [*drug therapy]; 6. Ibuprofen [*administration & dosage]; 7. Randomized Controlled Trials as Topic; 8. Time Factors;
MESH terms:
Antibiotics for preventing meningococcal infections
1. Ampicillin [therapeutic use]; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Ceftriaxone [therapeutic use]; 4. Ciprofloxacin [therapeutic use]; 5. Meningococcal Infections [*prevention & control]; 6. Minocycline [therapeutic use]; 7. Neisseria meningitidis; 8. Randomized Controlled Trials as Topic; 9. Rifampin [therapeutic use];
MESH terms:
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock
1. Age Factors; 2. Immunoglobulins, Intravenous [*therapeutic use]; 3. Randomized Controlled Trials as Topic; 4. Sepsis [*drug therapy, mortality]; 5. Shock, Septic [*drug therapy, mortality];
MESH terms:
Optimal timing for intravascular administration set replacement
1. Bacteremia [*prevention & control]; 2. Blood; 3. Catheter‐Related Infections [mortality, *prevention & control]; 4. Catheterization, Central Venous [instrumentation]; 5. Catheters, Indwelling [*statistics & numerical data]; 6. Device Removal [standards, *statistics & numerical data]; 7. Infusions, Intravenous [*instrumentation]; 8. Lipids; 9. Parenteral Nutrition [*instrumentation]; 10. Time Factors;
MESH terms:
Antibiotics for preventing complications in children with measles
1. Anti‐Bacterial Agents [*therapeutic use]; 2. Conjunctivitis, Bacterial [prevention & control]; 3. Croup [prevention & control]; 4. Diarrhea [prevention & control]; 5. Measles [*complications]; 6. Otitis Media [prevention & control]; 7. Pneumonia [drug therapy, *prevention & control]; 8. Randomized Controlled Trials as Topic; 9. Tonsillitis [prevention & control];
MESH terms:
Glucocorticoids for acute viral bronchiolitis in infants and young children
1. Acute Disease; 2. Ambulatory Care; 3. Bronchiolitis, Viral [*drug therapy]; 4. Dexamethasone [therapeutic use]; 5. Epinephrine [therapeutic use]; 6. Glucocorticoids [*therapeutic use]; 7. Hospitalization; 8. Randomized Controlled Trials as Topic; 9. Respiratory Sounds [etiology];
MESH terms:
Antibiotics for community‐acquired pneumonia in children
1. Amoxicillin [therapeutic use]; 2. Anti-Bacterial Agents [*therapeutic use]; 3. Chloramphenicol [therapeutic use]; 4. Community-Acquired Infections [drug therapy]; 5. Drug Therapy, Combination [methods]; 6. Gentamicins [therapeutic use]; 7. Penicillins [therapeutic use]; 8. Pneumonia, Bacterial [*drug therapy]; 9. Randomized Controlled Trials as Topic; 10. Trimethoprim, Sulfamethoxazole Drug Combination [therapeutic use];
MESH terms:
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children
1. Antibodies, Monoclonal, Humanized [*therapeutic use]; 2. Antiviral Agents [*therapeutic use]; 3. Hospitalization [statistics & numerical data]; 4. Palivizumab; 5. Randomized Controlled Trials as Topic; 6. Respiratory Syncytial Virus Infections [*prevention & control];
MESH terms:
De‐escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock
1. *Withholding Treatment; 2. Anti‐Bacterial Agents [*administration & dosage]; 3. Sepsis [*drug therapy]; 4. Shock, Septic [drug therapy];
MESH terms:
Co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection and AIDS
1. Acquired Immunodeficiency Syndrome [drug therapy]; 2. Alkynes; 3. Anti‐HIV Agents [adverse effects, *therapeutic use]; 4. Atazanavir Sulfate; 5. Benzoxazines [therapeutic use]; 6. Cyclopropanes; 7. Dideoxynucleosides [*therapeutic use]; 8. Drug Combinations; 9. HIV Infections [*drug therapy]; 10. Lamivudine [adverse effects, *therapeutic use]; 11. Nelfinavir [therapeutic use]; 12. Oligopeptides [therapeutic use]; 13. Pyridines [therapeutic use]; 14. Randomized Controlled Trials as Topic; 15. Zidovudine [adverse effects, *therapeutic use];
MESH terms:
Vaccines for preventing influenza in people with asthma
1. Asthma [*complications]; 2. Disease Progression; 3. Influenza Vaccines [adverse effects, *therapeutic use]; 4. Influenza, Human [complications, *prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Vaccines, Inactivated [adverse effects, therapeutic use];
MESH terms:
Extracorporeal membrane oxygenation for critically ill adults
1. *Cardiopulmonary Resuscitation; 2. Critical Illness [therapy]; 3. *Extracorporeal Membrane Oxygenation [adverse effects]; 4. Health Status; 5. *Heart Arrest;
MESH terms:
Mental Health First Aid as a tool for improving mental health and well‐being
1. Databases, Bibliographic; 2. *Drug-Related Side Effects and Adverse Reactions; 3. First Aid; 4. *Mental Disorders [therapy]; 5. Mental Health;
MESH terms:
Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones
1. *Kidney Calculi [surgery]; 2. *Lithotripsy [adverse effects, methods]; 3. *Nephrolithotomy, Percutaneous [adverse effects]; 4. Retreatment; 5. Treatment Outcome;
MESH terms:
Magnetic seizure therapy for people with schizophrenia
1. *Antipsychotic Agents [adverse effects]; 2. Memory Disorders; 3. *Schizophrenia [drug therapy];
MESH terms:
Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis
1. Administration, Inhalation; 2. Anti-Bacterial Agents [therapeutic use]; 3. *Cystic Fibrosis [complications]; 4. Digital Technology; 5. Nebulizers and Vaporizers; 6. Quality of Life;
MESH terms:
Carnitine supplements for people with chronic kidney disease requiring dialysis
1. *Carnitine [therapeutic use]; 2. *Renal Insufficiency, Chronic [complications, therapy];
MESH terms:
Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
1. *Antipsychotic Agents [adverse effects]; 2. Drug Tapering; 3. *Drug-Related Side Effects and Adverse Reactions; 4. Quality of Life; 5. Recurrence; 6. *Schizophrenia [drug therapy];
MESH terms:
Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease
1. *Anemia [drug therapy, etiology]; 2. *Cardiovascular Diseases; 3. Cause of Death; 4. Fatigue; 5. Hypoxia; 6. Iron [therapeutic use]; 7. *Renal Insufficiency, Chronic [therapy];
MESH terms:
Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms
1. *Antipsychotic Agents [adverse effects]; 2. *Catatonia [drug therapy]; 3. *Neuroleptic Malignant Syndrome [drug therapy]; 4. Risperidone [therapeutic use]; 5. *Schizophrenia [complications, drug therapy];
MESH terms:
Cognitive behavioural therapy (group) for schizophrenia
1. *Cognitive Behavioral Therapy [methods]; 2. Hallucinations [etiology, therapy]; 3. *Psychotic Disorders [therapy]; 4. Quality of Life; 5. *Schizophrenia [drug therapy];
MESH terms:
Negative pressure wound therapy for managing the open abdomen in non‐trauma patients
1. Abdomen; 2. *Negative-Pressure Wound Therapy [methods]; 3. Pain; 4. Randomized Controlled Trials as Topic; 5. Wound Healing; 6. *Wound Infection;
MESH terms:
Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
1. *Lower Urinary Tract Symptoms [surgery, therapy]; 2. Prostate [surgery]; 3. *Prostatic Hyperplasia [surgery, therapy]; 4. Systematic Reviews as Topic; 5. *Transurethral Resection of Prostate [adverse effects, methods];
MESH terms:
Self‐management interventions for people with chronic obstructive pulmonary disease
1. Hospitalization; 2. Outcome Assessment, Health Care; 3. *Pulmonary Disease, Chronic Obstructive [therapy]; 4. Quality of Life; 5. *Self-Management;
MESH terms:
Integrated disease management interventions for patients with chronic obstructive pulmonary disease
1. Disease Management; 2. Dyspnea; 3. Exercise Tolerance; 4. *Pulmonary Disease, Chronic Obstructive [therapy]; 5. Quality of Life;
MESH terms:
Preoperative hair removal to reduce surgical site infection
1. *Hair Removal [adverse effects]; 2. *Surgical Wound Infection [prevention & control];
MESH terms:
Exercise training for adult lung transplant recipients
1. Bias; 2. Bone Density; 3. Cause of Death; 4. *Exercise; 5. Exercise Tolerance; 6. Forced Expiratory Volume; 7. Lung Transplantation [*rehabilitation]; 8. Muscle Strength; 9. Program Evaluation; 10. Quality of Life; 11. Randomized Controlled Trials as Topic; 12. Resistance Training; 13. Time Factors; 14. *Transplant Recipients; 15. Walk Test;
MESH terms:
Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD)
1. Disease Progression; 2. Dyspnea [etiology, therapy]; 3. *Pulmonary Disease, Chronic Obstructive [drug therapy]; 4. Quality of Life; 5. Referral and Consultation; 6. *Telemedicine;
MESH terms:
Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3‐5D
1. Antibodies, Monoclonal [adverse effects, therapeutic use]; 2. Bias; 3. Bone Density [drug effects]; 4. Bone Density Conservation Agents [adverse effects, *therapeutic use]; 5. Denosumab [adverse effects, therapeutic use]; 6. Femur Neck [drug effects]; 7. Fractures, Spontaneous [epidemiology, prevention & control]; 8. Hip; 9. Indoles [adverse effects, therapeutic use]; 10. Lumbar Vertebrae [drug effects]; 11. Osteoporosis, Postmenopausal [drug therapy, mortality, *therapy]; 12. Parathyroid Hormone-Related Protein [adverse effects, therapeutic use]; 13. Raloxifene Hydrochloride [adverse effects, therapeutic use]; 14. Randomized Controlled Trials as Topic; 15. Renal Dialysis; 16. Renal Insufficiency, Chronic [*complications, therapy]; 17. Spinal Fractures [diagnostic imaging, prevention & control]; 18. Teriparatide [adverse effects, therapeutic use]; 19. Thiophenes [adverse effects, therapeutic use]; 20. *Watchful Waiting;
MESH terms:
Vitamin D supplementation for the treatment of COVID‐19: a living systematic review
1. 25-Hydroxyvitamin D 2 [blood]; 2. Adrenal Cortex Hormones [therapeutic use]; 3. Azithromycin [therapeutic use]; 4. Bias; 5. Calcifediol [*administration & dosage]; 6. Cause of Death; 7. Ceftriaxone [therapeutic use]; 8. Cholecalciferol [*administration & dosage]; 9. COVID-19 [blood, mortality]; 10. Drug Therapy, Combination; 11. Hydroxychloroquine [therapeutic use]; 12. Quality of Life; 13. Randomized Controlled Trials as Topic; 14. Vitamin D Deficiency [diagnosis]; 15. Vitamins [*administration & dosage];
MESH terms:
Digital interventions for the management of chronic obstructive pulmonary disease
1. Bias; 2. *Cell Phone; 3. Chronic Disease; 4. *Internet-Based Intervention; 5. Pulmonary Disease, Chronic Obstructive [*therapy]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Self-Management [*methods]; 9. Smartphone; 10. Walk Test;
MESH terms:
Exercise training for bronchiectasis
1. Bias; 2. Breathing Exercises; 3. Bronchiectasis [mortality, *rehabilitation]; 4. Cough [therapy]; 5. Disease Progression; 6. Dyspnea [rehabilitation]; 7. *Exercise; 8. *Exercise Tolerance; 9. Hospitalization; 10. Mental Health; 11. Physical Endurance; 12. Physical Functional Performance; 13. *Quality of Life; 14. Respiration Disorders [rehabilitation]; 15. Walk Test;
MESH terms:
High versus low positive end‐expiratory pressure (PEEP) levels for mechanically ventilated adult patients with acute lung injury and acute respiratory distress syndrome
1. Acute Disease; 2. Bias; 3. Intensive Care Units; 4. Length of Stay; 5. Oxygen Consumption; 6. Positive-Pressure Respiration [*methods, mortality]; 7. Randomized Controlled Trials as Topic; 8. Respiratory Distress Syndrome [mortality, *therapy]; 9. Tidal Volume; 10. Ventilator-Induced Lung Injury [mortality, *therapy];
MESH terms:
Prevention of depression in adults with long‐term physical conditions
1. Acute Coronary Syndrome [psychology]; 2. Antidepressive Agents [*therapeutic use]; 3. Bias; 4. Brain Injuries, Traumatic [psychology]; 5. Breast Neoplasms [psychology]; 6. Depression [epidemiology, *prevention & control]; 7. Head and Neck Neoplasms [psychology]; 8. Incidence; 9. Macular Degeneration [psychology]; 10. Primary Prevention [*methods]; 11. *Problem Solving; 12. Randomized Controlled Trials as Topic; 13. Stroke [psychology]; 14. Tertiary Prevention [*methods];
MESH terms:
Video games for people with schizophrenia
1. Activities of Daily Living; 2. Bias; 3. Cognitive Remediation [*methods]; 4. Confidence Intervals; 5. Patient Dropouts [statistics & numerical data]; 6. Physical Fitness; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Schizophrenia [*therapy]; 10. Schizophrenic Psychology; 11. Social Interaction; 12. Standard of Care; 13. *Video Games;
MESH terms:
Rehabilitation following surgery for flexor tendon injuries of the hand
1. Bias; 2. Exercise Therapy [adverse effects, methods]; 3. Exoskeleton Device; 4. Hand Injuries [*rehabilitation, surgery]; 5. Immobilization; 6. Laser Therapy; 7. Muscle Contraction [physiology]; 8. Postoperative Care [methods]; 9. Randomized Controlled Trials as Topic [statistics & numerical data]; 10. Range of Motion, Articular; 11. Rupture [rehabilitation, surgery]; 12. Tendon Injuries [*rehabilitation, surgery]; 13. Ultrasonic Therapy;
MESH terms:
Urgent‐start peritoneal dialysis versus conventional‐start peritoneal dialysis for people with chronic kidney disease
1. Case-Control Studies; 2. Catheter Obstruction [*etiology]; 3. Catheter-Related Infections [*etiology]; 4. Cohort Studies; 5. Dialysis Solutions; 6. Emergency Treatment [*adverse effects, methods]; 7. Hemorrhage [etiology]; 8. Peritoneal Dialysis [*adverse effects, methods, mortality]; 9. Peritonitis [etiology]; 10. Randomized Controlled Trials as Topic; 11. Renal Insufficiency, Chronic [*therapy]; 12. Time Factors; 13. Wound Healing;
MESH terms:
Maintenance treatment with antipsychotic drugs for schizophrenia
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Bias; 3. Dopamine Antagonists [adverse effects, therapeutic use]; 4. Employment [statistics & numerical data]; 5. Hospitalization [statistics & numerical data]; 6. Maintenance Chemotherapy [*methods]; 7. Patient Dropouts [statistics & numerical data]; 8. Placebos [therapeutic use]; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Recurrence; 12. Schizophrenia [drug therapy, *prevention & control]; 13. Secondary Prevention;
MESH terms:
Psychosocial interventions for conversion and dissociative disorders in adults
1. Anti-Anxiety Agents [therapeutic use]; 2. Conversion Disorder [*therapy]; 3. Diazepam [therapeutic use]; 4. Hypnosis; 5. Psychotherapy [methods]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Repositioning for pressure injury prevention in adults
1. Beds; 2. Cost-Benefit Analysis; 3. Patient Positioning [economics, *methods]; 4. Pressure Ulcer [*prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Time Factors;
MESH terms:
Pelvic floor muscle training for preventing and treating urinary and faecal incontinence in antenatal and postnatal women
1. Exercise Therapy [*methods]; 2. Fecal Incontinence [epidemiology, prevention & control, *therapy]; 3. *Pelvic Floor; 4. Postnatal Care; 5. Pregnancy Complications [epidemiology, prevention & control, *therapy]; 6. Prenatal Care; 7. Puerperal Disorders [epidemiology, prevention & control, *therapy]; 8. Randomized Controlled Trials as Topic; 9. Urinary Incontinence [epidemiology, prevention & control, *therapy];
MESH terms:
Non‐steroidal anti‐inflammatory drugs for acute low back pain
1. Acute Pain [*drug therapy]; 2. Anti‐Inflammatory Agents, Non‐Steroidal [adverse effects, *therapeutic use]; 3. Cyclooxygenase 2 Inhibitors [adverse effects, therapeutic use]; 4. Disability Evaluation; 5. Low Back Pain [*drug therapy]; 6. Pain Measurement; 7. Placebos [therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Subcuticular sutures for skin closure in non‐obstetric surgery
1. Cicatrix; 2. Dermatologic Surgical Procedures [*methods]; 3. Incidence; 4. Patient Satisfaction; 5. Randomized Controlled Trials as Topic; 6. Surgical Stapling; 7. Surgical Tape; 8. Surgical Wound Dehiscence [epidemiology]; 9. Surgical Wound Infection [epidemiology, prevention & control]; 10. *Suture Techniques [adverse effects, economics]; 11. Time Factors; 12. Tissue Adhesives;
MESH terms:
Epidural corticosteroid injections for lumbosacral radicular pain
1. Adrenal Cortex Hormones [*administration & dosage]; 2. Anesthetics, Local [*administration & dosage]; 3. Injections, Epidural [adverse effects, methods]; 4. Lumbosacral Region; 5. Randomized Controlled Trials as Topic; 6. Sciatica [*drug therapy];
MESH terms:
Benzodiazepines for treatment of patients with delirium excluding those who are cared for in an intensive care unit
1. *Critical Care; 2. *Palliative Care; 3. Antipsychotic Agents [*therapeutic use]; 4. Benzodiazepines [*therapeutic use]; 5. Delirium [*drug therapy]; 6. Haloperidol [therapeutic use]; 7. Lorazepam [therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Percutaneous pinning for treating distal radial fractures in adults
1. Bone Nails; 2. Bone Wires; 3. Casts, Surgical; 4. Colles' Fracture [surgery]; 5. Fracture Fixation [*instrumentation, *methods]; 6. Radius Fractures [*surgery]; 7. Randomized Controlled Trials as Topic; 8. Wrist Injuries [*surgery];
MESH terms:
Pharmacological interventions for treatment‐resistant depression in adults
1. *Antidepressive Agents [therapeutic use]; 2. *Antipsychotic Agents [therapeutic use]; 3. *Depression [drug therapy]; 4. Drug Resistance; 5. Drug Therapy, Combination; 6. Mianserin [therapeutic use]; 7. Patient Dropouts; 8. Randomized Controlled Trials as Topic; 9. Treatment Outcome;
MESH terms:
Transcutaneous electrical nerve stimulation (TENS) for chronic neck pain
1. Chronic Pain [*therapy]; 2. Neck Pain [*therapy]; 3. Pain Management; 4. Pain Measurement; 5. Randomized Controlled Trials as Topic; 6. Transcutaneous Electric Nerve Stimulation [*methods]; 7. Treatment Outcome;
MESH terms:
Modafinil for people with schizophrenia or related disorders
1. Antipsychotic Agents [therapeutic use]; 2. Cognition [drug effects, physiology]; 3. Modafinil [*therapeutic use]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Schizophrenia [*drug therapy]; 7. Wakefulness-Promoting Agents [*therapeutic use];
MESH terms:
Perioperative restrictive versus goal‐directed fluid therapy for adults undergoing major non‐cardiac surgery
1. *Surgical Procedures, Operative; 2. Fluid Therapy [*methods]; 3. Length of Stay; 4. Perioperative Care [*methods]; 5. Postoperative Complications [prevention & control]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Treatments for primary delusional infestation
1. *Psychotherapy; 2. Antipsychotic Agents [*therapeutic use]; 3. Randomized Controlled Trials as Topic; 4. Schizophrenia, Paranoid [*therapy]; 5. Self Concept;
MESH terms:
Interventions for prodromal stage of psychosis
1. *Cognitive Behavioral Therapy; 2. Antipsychotic Agents [*therapeutic use]; 3. Fatty Acids, Omega‐3 [*therapeutic use]; 4. Prodromal Symptoms; 5. Psychotic Disorders [diagnosis, *prevention & control]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Surgical versus conservative interventions for treating acromioclavicular dislocation of the shoulder in adults
1. Acromioclavicular Joint [*injuries]; 2. Immobilization [*methods]; 3. Joint Dislocations [surgery, *therapy]; 4. Randomized Controlled Trials as Topic; 5. Reoperation;
MESH terms:
Acetylsalicylic acid (aspirin) for schizophrenia
1. Anti‐Inflammatory Agents, Non‐Steroidal [*therapeutic use]; 2. Antipsychotic Agents [therapeutic use]; 3. Aspirin [*therapeutic use]; 4. Chemotherapy, Adjuvant; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Schizophrenia [*drug therapy];
MESH terms:
Rigid dressings versus soft dressings for transtibial amputations
1. *Bandages [adverse effects]; 2. *Wound Healing; 3. Amputation, Surgical [*methods]; 4. Compression Bandages [adverse effects]; 5. Length of Stay; 6. Postoperative Care [*instrumentation]; 7. Randomized Controlled Trials as Topic [statistics & numerical data]; 8. Selection Bias; 9. Tibia [*surgery]; 10. Time Factors; 11. Walking;
MESH terms:
Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease
1. Anti‐Bacterial Agents [*therapeutic use]; 2. Antibiotic Prophylaxis [*methods]; 3. Disease Progression; 4. Pulmonary Disease, Chronic Obstructive [*drug therapy]; 5. Quality of Life; 6. Treatment Outcome;
MESH terms:
Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease
1. Bronchitis, Chronic [*drug therapy, prevention & control]; 2. Disease Progression; 3. Expectorants [*therapeutic use]; 4. Pulmonary Disease, Chronic Obstructive [*drug therapy, prevention & control]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Treatment Outcome;
MESH terms:
Conservative management following closed reduction of traumatic anterior dislocation of the shoulder
1. *Conservative Treatment; 2. Immobilization [adverse effects, *methods]; 3. Joint Instability [etiology]; 4. Randomized Controlled Trials as Topic; 5. Shoulder Dislocation [complications, *therapy];
MESH terms:
Interventions for preventing high altitude illness: Part 3. Miscellaneous and non‐pharmacological interventions
1. Acetazolamide [therapeutic use]; 2. Altitude Sickness [*prevention & control]; 3. Brain Edema [prevention & control]; 4. Ginkgo biloba; 5. Hypertension, Pulmonary [prevention & control]; 6. Medroxyprogesterone [therapeutic use]; 7. Plant Extracts [therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Peer support for people with schizophrenia or other serious mental illness
1. *Peer Group; 2. *Schizophrenic Psychology; 3. *Social Support; 4. Quality of Life; 5. Recurrence; 6. Schizophrenia [*therapy];
MESH terms:
Subfascial endoscopic perforator surgery (SEPS) for treating venous leg ulcers
1. Compression Bandages; 2. Postoperative Complications; 3. Randomized Controlled Trials as Topic; 4. Recurrence; 5. Saphenous Vein [surgery]; 6. Time Factors; 7. Varicose Ulcer [*surgery]; 8. Vascular Surgical Procedures [adverse effects, methods]; 9. Veins [*surgery]; 10. Wound Healing;
MESH terms:
Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
1. *Water; 2. Ejaculation; 3. Lower Urinary Tract Symptoms [etiology, *surgery]; 4. Organ Size; 5. Penile Erection; 6. Prostate [pathology, *surgery]; 7. Prostatic Hyperplasia [complications, *surgery]; 8. Quality of Life; 9. Retreatment [statistics & numerical data]; 10. Robotic Surgical Procedures [*methods]; 11. Surgery, Computer‐Assisted [methods]; 12. Transurethral Resection of Prostate;
MESH terms:
Immunonutrition for acute respiratory distress syndrome (ARDS) in adults
1. Antioxidants [*administration & dosage, adverse effects]; 2. Cause of Death; 3. Docosahexaenoic Acids [administration & dosage]; 4. Eicosapentaenoic Acid [administration & dosage]; 5. Enteral Nutrition [adverse effects, *methods]; 6. Fatty Acids, Omega‐3 [*administration & dosage, adverse effects]; 7. Intensive Care Units [statistics & numerical data]; 8. Length of Stay; 9. Oxygen Inhalation Therapy [statistics & numerical data]; 10. Randomized Controlled Trials as Topic; 11. Respiration, Artificial [statistics & numerical data]; 12. Respiratory Distress Syndrome [mortality, *therapy]; 13. gamma‐Linolenic Acid [administration & dosage];
MESH terms:
Subacromial decompression surgery for rotator cuff disease
1. Acromion; 2. Arthroscopy; 3. Decompression, Surgical [adverse effects, *methods]; 4. Exercise Therapy; 5. Postoperative Complications; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Rotator Cuff [*surgery]; 9. Shoulder Impingement Syndrome [*surgery]; 10. Shoulder Pain [*surgery];
MESH terms:
Deep brain stimulation for dystonia
1. Age Factors; 2. Deep Brain Stimulation [*methods]; 3. Dystonic Disorders [*therapy]; 4. Globus Pallidus; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Torticollis [therapy];
MESH terms:
Effects of peri‐operative nonsteroidal anti‐inflammatory drugs on post‐operative kidney function for adults with normal kidney function
1. Acute Kidney Injury [chemically induced]; 2. Anti‐Inflammatory Agents, Non‐Steroidal [*adverse effects]; 3. Creatinine [blood]; 4. Kidney [*drug effects, physiology]; 5. Length of Stay; 6. Pain, Postoperative [*drug therapy]; 7. Perioperative Care; 8. Randomized Controlled Trials as Topic; 9. Renal Insufficiency [chemically induced]; 10. Urine;
MESH terms:
Laryngeal mask airway versus endotracheal tube for percutaneous dilatational tracheostomy in critically ill adults
1. *Critical Illness; 2. Dilatation [instrumentation]; 3. Intubation, Intratracheal [adverse effects, *instrumentation, mortality]; 4. *Laryngeal Masks [adverse effects]; 5. Randomized Controlled Trials as Topic; 6. Tracheostomy [adverse effects, instrumentation, *methods, mortality];
MESH terms:
Perioperative alcohol cessation intervention for postoperative complications
1. *Alcohol Abstinence; 2. Alcohol Drinking [adverse effects, epidemiology, *prevention & control]; 3. *Elective Surgical Procedures; 4. Hospital Mortality; 5. Perioperative Care; 6. Postoperative Complications [epidemiology, mortality, *prevention & control]; 7. Preoperative Care [*methods]; 8. Randomized Controlled Trials as Topic; 9. Secondary Prevention; 10. Substance Withdrawal Syndrome [prevention & control]; 11. Surgical Procedures, Operative [mortality];
MESH terms:
Chlorpromazine versus piperacetazine for schizophrenia
1. Antipsychotic Agents [adverse effects, *therapeutic use]; 2. Chlorpromazine [adverse effects, *therapeutic use]; 3. Phenothiazines [adverse effects, *therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Schizophrenia [*drug therapy]; 6. Treatment Outcome;
MESH terms:
Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
1. Amoxicillin [adverse effects, therapeutic use]; 2. Anti-Bacterial Agents [adverse effects, *therapeutic use]; 3. Antibiotic Prophylaxis [*methods]; 4. Aza Compounds [therapeutic use]; 5. Azithromycin [adverse effects, therapeutic use]; 6. Clarithromycin [therapeutic use]; 7. Clavulanic Acid [adverse effects, therapeutic use]; 8. *Disease Progression; 9. Drug Administration Schedule; 10. Erythromycin [therapeutic use]; 11. Fluoroquinolones; 12. Moxifloxacin [therapeutic use]; 13. Pulmonary Disease, Chronic Obstructive [*drug therapy]; 14. *Quality of Life; 15. Quinolines [therapeutic use]; 16. Randomized Controlled Trials as Topic; 17. Roxithromycin [adverse effects, therapeutic use]; 18. Trimethoprim, Sulfamethoxazole Drug Combination [adverse effects, therapeutic use];
MESH terms:
Antibiotics for exacerbations of chronic obstructive pulmonary disease
1. Ambulatory Care; 2. Anti-Bacterial Agents [adverse effects, *therapeutic use]; 3. Disease Progression; 4. Hospitalization; 5. Intensive Care Units; 6. Pulmonary Disease, Chronic Obstructive [classification, *drug therapy, mortality]; 7. Randomized Controlled Trials as Topic; 8. Treatment Failure;
MESH terms:
Occupational therapy delivered by specialists versus non‐specialists for people with schizophrenia
1. *Occupational Therapists; 2. *Specialization; 3. Occupational Therapy [*methods]; 4. Schizophrenia [*therapy];
MESH terms:
Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD)
1. Calcium [blood]; 2. Calcium Compounds [adverse effects, *therapeutic use]; 3. Cause of Death; 4. Chelating Agents [adverse effects, *therapeutic use]; 5. Chronic Disease; 6. Chronic Kidney Disease-Mineral and Bone Disorder [blood, *drug therapy, *prevention & control]; 7. Disease Progression; 8. Fibroblast Growth Factor-23; 9. Hypercalcemia [chemically induced]; 10. Iron Compounds [adverse effects, therapeutic use]; 11. Lanthanum [adverse effects, therapeutic use]; 12. Parathyroid Hormone [blood]; 13. Phosphorus [*blood]; 14. Polyamines [adverse effects, *therapeutic use]; 15. Randomized Controlled Trials as Topic; 16. Renal Dialysis [statistics & numerical data]; 17. Sevelamer [therapeutic use];
MESH terms:
Automated monitoring compared to standard care for the early detection of sepsis in critically ill patients
1. *Critical Illness; 2. Anti‐Bacterial Agents [therapeutic use]; 3. Early Diagnosis; 4. Intensive Care Units; 5. Length of Stay; 6. Randomized Controlled Trials as Topic; 7. Sepsis [*diagnosis, drug therapy]; 8. Time‐to‐Treatment;
MESH terms:
Fluphenazine (oral) versus placebo for schizophrenia
1. Administration, Oral; 2. Akathisia, Drug-Induced [epidemiology]; 3. Antipsychotic Agents [adverse effects, *therapeutic use]; 4. Fluphenazine [adverse effects, *therapeutic use]; 5. Placebos [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Schizophrenia [*drug therapy, mortality];
MESH terms:
Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults
1. Analgesia, Epidural; 2. Analgesics, Opioid [therapeutic use]; 3. Anesthetics, Intravenous [*administration & dosage, adverse effects]; 4. Anesthetics, Local [*administration & dosage, adverse effects]; 5. Ileus [epidemiology]; 6. Lidocaine [*administration & dosage, adverse effects]; 7. Nausea [epidemiology]; 8. Pain Measurement; 9. Pain, Postoperative [*drug therapy]; 10. Postoperative Complications [epidemiology]; 11. Randomized Controlled Trials as Topic; 12. Recovery of Function;
MESH terms:
Psychological therapies for treatment‐resistant depression in adults
1. Antidepressive Agents [therapeutic use]; 2. Cognitive Behavioral Therapy; 3. Depression [*therapy]; 4. Drug Resistance; 5. Psychotherapy [*methods]; 6. Psychotherapy, Group; 7. Randomized Controlled Trials as Topic;
MESH terms:
Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia
1. *Drug Substitution; 2. Antipsychotic Agents [*administration & dosage]; 3. Fluphenazine [*administration & dosage]; 4. Haloperidol [*administration & dosage]; 5. Schizophrenia [drug therapy]; 6. Treatment Outcome;